Shandong Boan Biotechnology Co., Ltd.
山东博安生物技术股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6955)

VOLUNTARY ANNOUNCEMENT

MARKETING AUTHORISATION APPLICATIONS FOR THE COMPANY'S TWO DENOSUMAB INJECTIONS ACCEPTED IN THE UK

The board of directors (the "**Board**") of Shandong Boan Biotechnology Co., Ltd. (the "**Company**") announces that the Marketing Authorisation Applications (MAAs) for its two denosumab injections, BA6101, a 60 mg denosumab injection for orthopedic indications, and BA1102, a 120 mg denosumab injection for oncology indications, have been accepted by the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom (UK).

As a biosimilar of Prolia®, BA6101 was already approved for marketing in the People's Republic of China ("**China**") in 2022 under the trade name Boyoubei®. It was the first domestically developed denosumab injection in China. The feedback on the product from physicians and patients has been positive over the past three years since its launch. The MAA for BA6101 in the UK has been accepted for the following proposed indications: 1) Treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures. In postmenopausal women, BA6101 significantly reduces the risk of vertebral, non-vertebral, and hip fractures; 2) Treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures. In men with prostate cancer receiving hormone ablation, BA6101 significantly reduces the risk of vertebral fractures; and 3) Treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fractures.

BA1102 is a biosimilar of Xgeva®. It was already approved for marketing in China in 2024 under the trade name Boluojia®. Its MAA in the UK covers the following proposed indications: 1) Prevention of skeletal-related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with advanced malignancies involving bone; and 2) Treatment of adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity.

BA6101 and BA1102 are core products developed by the Company under its global research and development strategy. The Company is actively conducting clinical trials abroad. In addition to the UK, the Company will also submit MAAs for BA6101 and BA1102 to the European Medicines Agency (EMA), the U.S. Food and Drug Administration (FDA), and Japan's Pharmaceuticals and Medical Devices Agency (PMDA).

Driven by broad clinical needs and well-established therapeutic benefits, denosumab has demonstrated substantial market potential worldwide. Publicly available data shows that the combined worldwide sales of Prolia® and Xgeva® in 2024 were approximately USD 6.6 billion. To support its global commercial goals, the Company has established a quality management system in line with Chinese, American, European, and Japanese standards, to ensure the quality of denosumab and other subsequent biologics for exporting abroad.

By Order of the Board
Shandong Boan Biotechnology Co., Ltd.
Jiang Hua
Chairlady, Chief Executive Officer and Executive Director

Yantai, the People's Republic of China, 7 November 2025

As at the date of this announcement, the executive directors of the Company are Ms. Jiang Hua, Dr. Dou Changlin and Mr. Wang Shenghan; the non-executive directors of the Company are Mr. Liu Yuanchong, Ms. Li Li and Mr. Li Shixu; and the independent non-executive directors of the Company are Professor Shi Luwen, Mr. Dai Jixiong and Dr. Yu Jialin.